Please use this identifier to cite or link to this item:
|Title:||PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up.||Austin Authors:||Ong, Sean;Pascoe, Claire;Kelly, Brian D ;Ballok, Zita;Webb, David ;Bolton, Damien M ;Murphy, Declan;Sengupta, Shomik ;Bowden, Patrick;Lawrentschuk, Nathan||Affiliation:||Olivia Newton-John Cancer Wellness and Research Centre..
Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3051, Australia..
Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia..
EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Richmond, VIC 3121, Australia..
Young Urology Researcher's Organisation, Melbourne, VIC 3000, Australia..
Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia..
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia..
Department of Nuclear Medicine, Richmond Medical Imaging, Richmond, VIC 3121, Australia..
Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia..
|Issue Date:||31-May-2022||Date:||2022||Publication information:||Cancers 2022-05-31; 14(11) 2717.||Abstract:||Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) is a novel imaging modality used to stage recurrent prostate cancer. It has the potential to improve prognostication and ultimately guide the timing of treatment for men with recurrent prostate cancer. This study aims to assess the clinical impact of PSMA PET-CT by analyzing its predictive value of treatment progression after 3 years of follow-up. In this prospective cohort study of 100 men, patients received a PSMA PET-CT for restaging of their disease which was used by a multi-disciplinary team to make a treatment decision. The primary endpoint was treatment progression. This was defined as the addition or change of any treatment modalities such as androgen deprivation therapy (ADT), radiation therapy or chemotherapy. The median follow-up time was 36 months (IQR 24-40 months). No treatment progression was found in 72 (75%) men and therefore 24 (25%) patients were found to have treatment progression. In men with a negative PSMA PET-CT result, 5/33 (15.1%) had treatment progression and 28/33 (84.8%) had no treatment progression. In conclusion, clinical decisions made with PSMA PET-CT results led to 75% of men having no treatment progression at 3 years of follow-up. In men with negative PSMA PET-CT results, this increased to 85% of men.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30307||DOI:||10.3390/cancers14112717||ORCID:||0000-0003-1117-2409
|Journal:||Cancers||PubMed URL:||35681697||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/35681697/||ISSN:||2072-6694||Type:||Journal Article||Subjects:||PSMA PET-CT
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 1, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.